EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID ‐ NET : A Cohort Study in Japan

Yusuke Okada iD, Kazuhiro Kajiyama iD, Maki Komamine, Takashi Ando iD, Tomoaki Hasegawa iD, Chieko Ishiguro iD, Takahiro Nonaka, Mariko Tsukuda, Yukari Iwasaki, Takahiro Ueda, Naoya Horiuchi, Toyotaka Iguchi und 1 weitere

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70268 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Yusuke Okada und 12 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Hauptthemen laut MEDLINE: Thrombocytopenia, Selective Serotonin Reuptake Inhibitors, Serotonin and Noradrenaline Reuptake Inhibitors, Depression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Risk assessment on thrombocytopenia by selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs) is limited. An observational study with cohort design was conducted based on the MID‐NET for evaluating the risk of thrombocytopenia by SSRIs and SNRIs in patients with depression compared to paroxetine. The exposure group was categorized as each drug of SSRIs/SNRIs, SSRIs group (escitalopram, sertraline, fluvoxamine), SNRIs group (duloxetine, venlafaxine, milnacipran), or vortioxetine. We estimated the adjusted hazard ratio (aHR) of each drug compared to paroxetine for the risk of thrombocytopenia (platelet count < 100,000/mm 3 ). More severe definitions were used in sensitivity analyses. In all, 4759 patients (median age: 49 years; 31.6% male) on SSRIs, 3440 patients (62 years; 38.6% male) on SNRIs, 12 patients (42.5 years; less than 83.4% male) on vortioxetine, and 2196 patients on paroxetine (62 years; 33.2% male) were included for analysis. Compared with paroxetine, the aHRs (95% confidence interval) of SSRIs group and SNRIs group were 1.14 (0.76–1.70) and 0.77 (0.48–1.21), respectively. Among SSRIs, sertraline and fluvoxamine showed a relatively higher point estimate of aHR > 1.0 (1.23 [95% confidence interval: 0.78–1.94] and 1.48 [0.87–2.51], respectively). The consistent results were also observed in the sensitivity analyses. The results suggest that the risk of thrombocytopenia by sertraline or fluvoxamine was comparable to that by paroxetine, known as having the risk of thrombocytopenia, leading to the revision of the sertraline package insert as a regulatory safety measure. Prescribers and clinicians may need to be vigilant to the possibility of sertraline‐induced thrombocytopenia in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombocytopeniaSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsDepressionHumansMaleFemaleMiddle AgedJapanAdultRisk AssessmentAgedSertralineParoxetineCohort StudiesRisk FactorsFluvoxamine

Stichwörter der Autor:innen

depressiondrug safetypharmacoepidemiologythrombocytopenia

Substanzen

Selective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsSertralineParoxetineFluvoxamine

Autor:innen und Institutionen

  • Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Office of Regulatory Science Research, Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

ORCID-Profile: Yusuke Okada, Kazuhiro Kajiyama, Takashi Ando, Tomoaki Hasegawa, Chieko Ishiguro, Yoshiaki Uyama

Zitieren

APA

Okada, Y., Kajiyama, K., Komamine, M., Ando, T., Hasegawa, T., Ishiguro, C., Nonaka, T., Tsukuda, M., Iwasaki, Y., Ueda, T., Horiuchi, N., Iguchi, T., & Uyama, Y. (2025). Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID ‐ NET : A Cohort Study in Japan. Clinical and Translational Science. https://doi.org/10.1111/cts.70268

Vancouver

Okada Y, Kajiyama K, Komamine M, Ando T, Hasegawa T, Ishiguro C, et al. Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID ‐ NET : A Cohort Study in Japan. Clinical and Translational Science. 2025. doi:10.1111/cts.70268

BibTeX
@article{Okada2025,
  author = {Okada, Yusuke and Kajiyama, Kazuhiro and Komamine, Maki and Ando, Takashi and Hasegawa, Tomoaki and Ishiguro, Chieko and Nonaka, Takahiro and Tsukuda, Mariko and Iwasaki, Yukari and Ueda, Takahiro and Horiuchi, Naoya and Iguchi, Toyotaka and Uyama, Yoshiaki},
  title = {Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID ‐ NET : A Cohort Study in Japan},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70268}
}
Kostenlos starten →